drugset / Trial / NCT06859775
SHR-A1811 Combination Regimen for the Treatment of Recurrent or Metastatic Cervical Cancer
RandomizedSingle-groupOpen-labelTreatment
Summary
This study is a multicentre, open-label, dose-finding/efficacy-expanding phase Ib/II clinical trial to evaluate the tolerability, safety, pharmacokinetic profile and immunogenicity of SHR-A1811 combination regimen in the treatment of recurrent or metastatic cervical cancer and to preliminarily evaluate the efficacy of SHR-A1811 combination regimen for recurrent or metastatic cervical cancer.
Timeline
- Start
- 2025-04-25
- Primary completion
- 2026-10
- Completion
- 2027-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Adebelimab | Unknown | — | Other |
| Subject | Bevacizumab | Monoclonal antibody | — | Other |
| Subject | Carboplatin | Small molecule | — | Other |
| Subject | Cisplatin | Other / unclassified | — | Other |
| Subject | SHR-8068 | Monoclonal antibody | — | Other |
| Subject | SHR-A1811 | Monoclonal antibody | — | Other |
Indications
No indication recorded.